Skip to main
HSIC

Henry Schein (HSIC) Stock Forecast & Price Target

Henry Schein (HSIC) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 14%
Buy 43%
Hold 36%
Sell 7%
Strong Sell 0%

Bulls say

Henry Schein is expected to continue performing well due to its strong market demand, improved margins, and focus on growth. With new leadership and a resilient dental market, the company is well-positioned for international growth. Although there are concerns about potential changes in the economy and healthcare policies, the company’s positive outlook is further supported by its strong financials and successful transformations. Omnicell, a competing healthcare company, has also shown positive growth but faces integration challenges with recent acquisitions, making Henry Schein a more appealing investment option.

Bears say

Henry Schein is well-positioned in the dental market and global segments, however, there are concerns about its slow growth in the US due to a security breach and potential impacts from tariffs. Profitability is expected to improve with its value creation initiatives and partnerships, but there may be challenges in reaching previous levels of growth in the US market. Overall, while the company may face some short-term challenges, it is still a strong player in the healthcare industry and has potential for long-term growth.

Henry Schein (HSIC) has been analyzed by 14 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 43% recommend Buy, 36% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Henry Schein (HSIC) Forecast

Analysts have given Henry Schein (HSIC) a Buy based on their latest research and market trends.

According to 14 analysts, Henry Schein (HSIC) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Henry Schein (HSIC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.